Case Study: Matrixx Initiatives Inc. V. Siracusano
January 18, 2011, 1:25 PM EST
Law360, New York (January 18, 2011, 1:25 PM EST) -- The U.S. Supreme Court heard oral arguments on Jan. 10, 2011, in Matrixx Initiatives Inc. v. Siracusano, No. 09-1156, a securities fraud case in which the court is expected to address the question of whether pharmaceutical company Matrixx Initiatives Inc. was required to disclose reports of adverse events following the use of its cold remedy product even though the reports are not alleged by the plaintiffs to have been statistically significant.
Although the question presented is limited, in deciding this case, the court may provide more...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.